@entity1893 and " XXXX ": long-term results with the modified LSA2-L2 protocol.

@entity1 @entity6220 @entity981 @entity706 @entity3480 @entity1893
From June 1976 to December 1984, 48 previously untreated @entity1 with @entity1893 ( @entity1893 ) were treated according to the LSA2-L2 protocol, modified by inclusion of cranial irradiation for @entity1 in stage III and stage IV disease. According to the staging system proposed by Wollner, 4 @entity1 were in stage I, 8 in stage II, 11 in stage III, 8 in stage @entity3480 (less than or equal to 25% blasts in the bone marrow), 15 in stage IVB (greater than 25% blasts in the bone marrow), and 2 in @entity6220 . The complete remission rate was 95.8%. The relapse-free survival (RFS) rate of 46 complete responders was 76% after a median observation time of 47+ months. Only 1 of 35 high-risk responder @entity1 developed CNS relapse after prophylactic treatment. Clinical stages were related to the RFS: 100% in stage I-II vs. 69% in stage III-IV. All 8 @entity1 in stage IV were alive without evidence of disease with a median observation time of 59+ months. Fifteen @entity1 in stage IVB who had @entity706 attained 59% RFS with a median observation time of 39+ months. After a median observation time of 38+ months, 29 of 37 @entity1 are off therapy. The results emphasize the value of both the histologic and immunologic features and the stage of disease in predicting the outcome of @entity1893 in @entity1 . The LSA2-L2 regimen appears to be a very effective protocol for @entity1 with @entity981 , although it may be less efficacious for @entity1 with large bone marrow involvement.
